Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Colorado State University
Taiho Oncology, Inc.
Essen Biotech
Institut Bergonié
OncoNano Medicine, Inc.
Incyte Corporation
Washington University School of Medicine
Incyte Corporation
Novartis
RAPT Therapeutics, Inc.
ModernaTX, Inc.
Cedars-Sinai Medical Center
Stingthera, Inc.
City of Hope Medical Center
Fate Therapeutics
Blue Note Therapeutics
Incyte Corporation
AstraZeneca
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Jonsson Comprehensive Cancer Center
MultiVir, Inc.
Celgene
Tocagen Inc.
Shenzhen BinDeBio Ltd.
Tel-Aviv Sourasky Medical Center
Novartis
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Amgen
OHSU Knight Cancer Institute
Ohio State University Comprehensive Cancer Center
University of Minnesota
Rutgers, The State University of New Jersey
Barbara Ann Karmanos Cancer Institute
University of Washington
Eastern Cooperative Oncology Group
Valerio Therapeutics
Indiana University
University of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Altor BioScience
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
National Cancer Institute (NCI)
University of Kentucky
National Cancer Institute (NCI)